Trial · NCT07884669
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Diagnostic performance of salivary and gastric juice biomarker signatures for identifying gastric and gastroesophageal junction cancer (GEC). | At gastroscopy | Presence or absence of gastric or gastroesophageal junction cancer confirmed by histopathological examination following gastroscopy. Biomarker signatures derived from salivary and gastric juice miRNA expression profiles and microbiome composition will be evaluated through positive predictive value to discriminate patients with GEC from patients without GEC. |
| Secondary | Presence of circulating tumor DNA (ctDNA) at baseline. | Baseline (C1D1 pre-dose) | Detection of ctDNA in plasma collected at treatment initiation in patients with non operable GEC. Percentage of participants with detectable ctDNA. |
| Secondary | Longitudinal variation of ctDNA. | From baseline through disease progression (up to 24 months after last patient enrolled) | Changes in ctDNA levels measured in serial plasma samples collected during follow-up. |
| Secondary | Association between ctDNA status and progression-free survival. | Up to 24 months after last patient enrolled | Progression-free survival according to detectable versus non-detectable ctDNA. |
| Secondary | Association between ctDNA status and overall survival. | Up to 24 months after last patient enrolled | Overall survival according to detectable versus non-detectable ctDNA. |
| Secondary | Plasma cytokine concentrations at baseline. | Baseline (C1D1 pre-dose) | Plasma concentrations of cytokines measured using multiplex cytokine assays in patients with non operable GEC. |
| Secondary | Association between cytokine concentrations and progression occurrence. | Up to 24 months after last patient enrolled | |
| Secondary | Progression-free survival according to cytokine concentrations. | Up to 24 months after last patient enrolled | |
| Secondary | Overall survival according to cytokine concentrations. | Up to 24 months after last patient enrolled | |
| Secondary | Tumor transcriptomic profiles measured by RNA sequencing. | At gastroscopy and at disease progression (if available) | Transcriptomic signatures identified using RNA sequencing on tumor samples collected at diagnosis and, if available, at disease progression. |
| Secondary | Tumor microenvironment characteristics measured by multiplex immunofluorescence (multi IF). | At gastroscopy and at disease progression (if available) | Characterization of immune and stromal cell populations in tumor samples using multi IF. |
| Secondary | Association between microenvironment features and disease progression occurrence. | Up to 24 months after last patient enrolled | |
| Secondary | Overall survival associated with tumor microenvironment features. | Up to 24 months after last patient enrolled | |
| Secondary | Performance of an integrated multi-parametric biomarker model for prediction of survival outcomes. | Up to 24 months after last patient enrolled | Integration of microbiome and miRNA signatures on saliva and gastric juice, ctDNA, plasma cytokine, tumor micro-environment features for the prediction of survival outcomes in patients with GEC . |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07884669/registered